Paras Biopharmaceuticals – advancing microbial biologics development technologies with customer-centric approach for meeting unmet medical needs

Located in the innovative and technology-advanced city of Oulu, Paras Biopharmaceuticals brings in a unique mix of world-class microbial biologics development technologies and a sound understanding of customer needs for development and production of recombinant biologics. Paras Biopharmaceuticals was founded in 2012 and since has seen significant growth in its microbial recombinant-therapeutics technology solutions. Paras Biopharma team has consolidated experience in developing complex proteins in a highly efficient manner.

Paras Biopharmaceuticals is at the forefront of providing solutions in the space of complex biologics. Being a lean company, the company has flexibility to adapt to the rapidly changing technologies and to Biopharma company needs. The company decision making is decentralized, and the core team has high flexibility for decision making. This enables to maintain a high level of customer satisfaction and speed in developing the medicines for unmet medical needs.

About Paras Biopharmaceuticals Finland Oy

Paras Biopharmaceuticals is an Oulu-based company having niche expertise in the production of microbial-based biopharmaceutical materials. Since its inception in 2012, the company has developed a robust portfolio of bioprocess technologies for the efficient biomanufacturing of complex and “difficult to do” biologics for rare and orphan diseases.

Contract development & microbial biologics manufacturing (CDMO)

Offers end-to-end services to produce microbial recombinant proteins from early-stage (20L), scale-up (150L) to large-scale (750L).

Development of biosimilar technologies and partnership

Actively engaged in R&D and is offering partnership for further development (including clinical development) on Recombinant Teriparatide (Forteo® Biosimilar), Recombinant IL1-RA / Anakinra (Kineret® Biosimilar), Analog Insulin Aspart and Recombinant Romiplostim (Nplate® Biosimilar). * Further biologics are in the pipeline.

Development of Recombinant expression systems and process technologies for biologics

Due to its own portfolio of proprietary technologies: Diabrid®, Noblecleav®, Biomultifold® and Cytofold StructQuant®, the company has achieved efficient and cost-effective ways which would help in the efficient production of some high-value biosimilars and biologics.

Recombinant Bioprocess Enzymes

Has developed and is offering recombinant bioprocess enzymes used in the cleavage of fusion proteins including Recombinant Enterokinase & Tev Protease.

*Forteo®, Kineret® & Nplate® are registered trademarks of Eli Lilly USA, Swedish Orphan Biovitrum AB and Amgen USA, respectively.

For further information:

Visit the company website:

Get in touch with Paras Biopharmaceuticals: